Lakefront Biotherapeutics revenue and financials
In the fiscal year ended December 2025, Lakefront Biotherapeutics reported revenue of €1.11B (+303.50% year over year). Net income was €320.88M, a net margin of 28.9%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +303.50%
- 2025 vs 2024
- Net income growth
- +333.15%
- 2025 vs 2024
- Net margin
- 28.9%
- 2024: 26.9%
How Lakefront Biotherapeutics is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 18.4% a year on average over the last 5 years
Compound annual growth rate: from €478.05M in 2020 to €1.11B in 2025.
Operating margin rose from −54.3% to 48.1%
Operating income over revenue, 2022 → 2025: 102.4 percentage points.
Profitable in 3 of 5 fiscal years
Positive net income, fiscal years 2021–2025.
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 1,112 | 276 | 240 | 241 | 234 | 478 | 835 | 318 | 156 | 152 |
| Cost of revenue | 489 | 370 | 241 | 270 | 321 | 524 | 420 | 323 | 219 | 72.0 |
| Gross profit | 623 | -94.7 | -1.6 | -28.5 | -86.1 | -45.6 | 415 | -5.0 | -62.6 | 79.6 |
| Selling, general and administrative | 141 | 133 | 131 | 139 | 132 | 185 | 97.0 | 39.8 | 27.2 | 23.5 |
| Research and development | 459 | 335 | 241 | 270 | — | — | — | — | — | 67.6 |
| Operating income | 535 | -187 | -85.1 | -131 | -172 | -179 | 369 | -44.8 | -89.8 | -11.5 |
| EBIT | 535 | -187 | -85.1 | -131 | -172 | -179 | 369 | -44.8 | -89.8 | -11.5 |
| EBITDA | 568 | -153 | -41.5 | -65.5 | -163 | -171 | 374 | -40.4 | -86.2 | -8.2 |
| Interest expense | 1.0 | 0.9 | 1.8 | 6.9 | 11.6 | 9.4 | 1.3 | 0.8 | 0.9 | 0.0 |
| Pre-tax income | 301 | -3.1 | 5.6 | -70.8 | -119 | -310 | 149 | -29.2 | -116 | 54.2 |
| Income tax | -18.6 | -1.8 | 9.6 | 0.6 | 1.4 | 1.2 | -0.2 | 0.1 | 0.2 | 0.2 |
| Net income | 321 | 74.1 | 212 | -218 | -103 | -305 | 150 | -29.3 | -116 | 54.0 |
| Net income to common shareholders | 319 | -1.3 | -4.0 | -71.4 | -121 | -311 | 149 | -29.3 | -116 | 54.0 |
| Basic EPS | 4.85 | -0.02 | -0.06 | -1.09 | -1.84 | -4.78 | 2.58 | -0.56 | -2.34 | 1.18 |
| Diluted EPS | 4.85 | -0.02 | -0.06 | -1.09 | -1.84 | -4.78 | 2.47 | -0.56 | -2.34 | 1.14 |
| Average shares (basic) | 65.9 | 65.9 | 65.9 | 65.7 | 65.5 | 65.1 | 57.6 | 52.1 | 49.5 | 45.7 |
| Average shares (diluted) | 65.9 | 65.9 | 65.9 | 65.7 | 65.5 | 65.1 | 60.1 | 52.1 | 49.5 | 47.3 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 12.1 | 6.5 | 901 | 71.2 | 65.3 | 75.0 | — | 59.8 | 77.9 | 62.4 | — | 120 |
| Cost of revenue | 34.7 | 35.8 | 108 | 84.7 | 42.3 | 196 | — | 93.1 | 90.2 | 74.2 | — | 318 |
| Gross profit | -22.6 | -29.3 | 793 | -13.6 | 23.0 | -122 | — | -33.2 | -12.3 | -11.7 | — | -198 |
| Selling, general and administrative | 22.5 | 35.5 | 32.3 | 34.5 | 14.1 | 43.8 | — | 29.3 | 33.1 | 30.8 | — | 60.6 |
| Research and development | 25.5 | 31.0 | 108 | 73.9 | 95.3 | — | — | — | — | — | — | -212 |
| Operating income | -43.5 | -63.7 | 793 | -41.7 | 17.3 | -159 | — | -54.3 | -38.2 | -33.1 | — | -30.2 |
| EBIT | -43.5 | -63.7 | 793 | -41.7 | 17.3 | -159 | — | -54.3 | -38.2 | -33.1 | — | -30.2 |
| EBITDA | -42.0 | -55.5 | 801 | -33.2 | 35.5 | -150 | — | -48.5 | -29.1 | -27.3 | — | -26.1 |
| Interest expense | 0.1 | — | 1.0 | — | 0.3 | — | — | 0.7 | — | 0.3 | — | 4.1 |
| Pre-tax income | 2.0 | 14.0 | 783 | -221 | -104 | -156 | — | -49.1 | 4.1 | 22.9 | — | 25.7 |
| Income tax | 0.1 | 0.1 | 0.7 | -17.5 | 0.0 | -1.8 | — | -0.6 | -0.6 | -0.6 | — | -0.1 |
| Net income | 2.1 | 14.5 | 782 | -202 | -106 | -153 | — | -50.4 | 9.0 | 90.2 | — | 25.8 |
| Net income to common shareholders | 2.1 | 14.5 | 782 | -202 | -106 | -153 | — | -50.4 | 9.0 | 90.2 | — | 25.8 |
| Basic EPS | 0.03 | 0.22 | 11.87 | -3.07 | -1.60 | -2.33 | — | -0.76 | 0.14 | 1.37 | — | 0.39 |
| Diluted EPS | 0.03 | 0.22 | 11.87 | -3.07 | -1.60 | -2.33 | — | -0.77 | 0.14 | 1.37 | — | 0.39 |
| Average shares (basic) | 65.9 | 65.9 | 65.9 | 65.9 | 66.0 | 65.8 | — | 65.9 | 65.9 | 65.9 | — | 66.3 |
| Average shares (diluted) | 66.0 | 65.9 | 65.9 | 65.9 | 66.0 | 65.8 | — | 65.9 | 66.2 | 65.9 | — | 66.3 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 3,407 | 4,136 | 4,357 | 4,734 | 5,193 | 5,718 | 6,069 | 1,439 | 1,286 | 1,083 |
| Current assets | 3,079 | 3,339 | 3,862 | 4,237 | 4,862 | 5,369 | 5,866 | 1,329 | 1,198 | 1,007 |
| Cash and equivalents | 87.9 | 64.2 | 167 | 508 | 2,233 | 2,135 | 1,862 | 1,291 | 1,151 | 973 |
| Short-term investments | 2,910 | 3,053 | 3,518 | 3,586 | 2,470 | 3,026 | 3,919 | — | — | — |
| Receivables | 53.2 | 88.1 | 65.7 | 77.3 | 129 | 173 | 80.1 | 33.5 | 41.8 | 23.5 |
| Inventory | 22.5 | 51.2 | 74.0 | 52.9 | 20.6 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 |
| Net property, plant and equipment | 80.7 | 123 | 126 | 154 | 138 | 103 | 66.1 | 23.1 | 16.7 | 15.0 |
| Goodwill | 0.0 | 70.0 | 69.6 | 69.8 | — | — | — | — | — | — |
| Other intangible assets | 0.8 | 158 | 119 | 136 | 48.3 | 54.2 | 10.1 | 3.6 | 2.5 | 1.0 |
| Long-term investments | 46.8 | 253 | 13.6 | 0.0 | — | 9.0 | 11.3 | 6.0 | 1.8 | 2.4 |
| Current liabilities | 153 | 335 | 428 | 523 | 566 | 635 | 572 | 220 | 172 | 104 |
| Accounts payable | 32.6 | 64.2 | 135 | 133 | 134 | 171 | 143 | 68.0 | 47.1 | 31.2 |
| Total debt | 6.9 | 11.7 | 9.6 | 21.9 | 26.9 | 29.4 | 25.4 | — | 0.0 | 0.1 |
| Total liabilities | 171 | 1,239 | 1,562 | 2,208 | 2,550 | 3,047 | 3,193 | 225 | 274 | 325 |
| Total equity (incl. minority) | 3,236 | 2,897 | 2,796 | 2,526 | 2,643 | 2,670 | 2,876 | 1,214 | 1,012 | 759 |
| Retained earnings | 211 | -134 | -228 | -497 | -367 | -335 | -109 | -298 | -211 | -112 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 3,351 | 3,372 | 3,407 | 3,512 | 3,818 | 4,022 | 4,136 | 4,172 | 4,290 | 4,361 | 4,357 | 4,451 |
| Current assets | 2,309 | 3,061 | 3,079 | 3,162 | 3,255 | 3,472 | 3,339 | 3,559 | 3,665 | 3,786 | 3,862 | 3,956 |
| Cash and equivalents | 136 | 66.8 | 87.9 | 64.5 | 71.7 | 108 | 64.2 | 55.5 | 72.3 | 73.4 | 167 | 159 |
| Short-term investments | 2,104 | 2,915 | 2,910 | 2,986 | 3,020 | 3,189 | 3,053 | 3,283 | 3,358 | 3,485 | 3,518 | 3,652 |
| Receivables | 56.3 | 54.0 | 53.2 | 77.7 | 87.8 | 83.5 | 88.1 | 87.2 | 102 | 92.0 | 65.7 | 73.0 |
| Inventory | 8.5 | 17.7 | 22.5 | 22.9 | 33.8 | 38.5 | 51.2 | 65.6 | 63.4 | 80.6 | 74.0 | 55.6 |
| Net property, plant and equipment | 76.9 | 77.0 | 80.7 | 106 | 110 | 113 | 123 | 132 | 128 | 125 | 126 | 137 |
| Goodwill | — | — | 0.0 | 0.0 | 69.2 | 69.7 | 70.0 | 69.5 | 69.8 | 69.7 | 69.6 | 69.9 |
| Other intangible assets | 751 | 0.7 | 0.8 | 7.4 | 147 | 156 | 158 | 173 | 183 | 126 | 119 | 132 |
| Long-term investments | 73.9 | 47.9 | 46.8 | 46.8 | 46.9 | 50.9 | 253 | 49.1 | 51.4 | — | 13.6 | — |
| Current liabilities | 70.3 | 100 | 153 | 367 | 403 | 437 | 335 | 351 | 365 | 382 | 428 | 444 |
| Accounts payable | 66.3 | 95.8 | 32.6 | 101 | 133 | 169 | 64.2 | 116 | 128 | 146 | 135 | 121 |
| Total debt | 6.4 | 6.4 | 6.9 | 7.5 | 8.4 | 10.9 | 11.7 | 11.5 | 10.9 | 8.0 | — | — |
| Total liabilities | 87.6 | 119 | 171 | 1,065 | 1,174 | 1,274 | 1,239 | 1,310 | 1,380 | 1,466 | 1,562 | 1,830 |
| Total equity (incl. minority) | 3,264 | 3,253 | 3,236 | 2,447 | 2,644 | 2,748 | 2,897 | 2,863 | 2,910 | 2,895 | 2,796 | 2,622 |
| Retained earnings | 234 | 228 | 211 | -578 | -381 | -281 | -134 | -164 | -119 | -133 | -228 | -403 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -257 | -320 | -406 | -501 | -504 | -427 | 3,209 | -142 | -147 | 239 |
| Depreciation and amortization | 36.8 | 38.3 | 43.6 | 65.6 | 16.2 | 14.8 | 11.1 | 4.4 | 3.6 | 3.3 |
| Capital expenditure | -13.7 | -16.7 | -18.7 | -27.4 | -54.2 | -42.5 | -22.4 | -10.4 | -5.3 | -4.5 |
| Investing cash flow | 289 | 221 | 71.2 | -1,246 | 541 | 757 | -3,765 | -15.9 | -0.5 | -7.3 |
| Financing cash flow | -3.3 | -4.9 | -5.0 | -1.5 | -3.9 | 22.0 | 1,336 | 288 | 353 | 396 |
| Debt repaid | -3.3 | -4.9 | -6.8 | -8.2 | -7.2 | -6.2 | -5.1 | -0.0 | -0.1 | -0.0 |
| Effect of exchange rates | -4.5 | 1.8 | -1.5 | 22.3 | 56.8 | -70.5 | -10.0 | 10.1 | -27.8 | 4.8 |
| Net change in cash | 23.6 | -103 | -341 | -1,725 | 90.3 | 281 | 571 | 140 | 178 | 633 |
| Free cash flow | -271 | -337 | -425 | -528 | -558 | — | — | — | — | — |
| Levered free cash flow | 345 | -274 | -119 | -23.6 | -119 | -170 | 534 | 46.2 | 12.2 | 34.8 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -34.1 | -82.8 | -47.5 | -62.6 | -109 | -38.6 | -71.8 | -66.4 | -122 | -119 | -125 | -94.9 |
| Depreciation and amortization | 3.0 | — | 36.8 | -36.5 | 36.5 | — | -18.2 | 18.2 | — | -18.6 | 18.6 | — |
| Capital expenditure | -0.0 | -0.1 | -1.6 | -2.9 | -4.2 | -5.1 | -4.2 | -3.3 | -3.7 | -3.0 | -3.8 | -4.3 |
| Investing cash flow | 101 | 61.5 | 72.6 | 56.7 | 74.7 | 84.7 | 56.6 | 66.0 | 29.7 | 183 | 101 | -289 |
| Financing cash flow | -3.9 | -0.5 | -0.4 | -1.3 | -0.6 | -1.0 | -1.1 | -1.1 | -1.2 | -2.1 | -1.6 | -0.2 |
| Share repurchases | -2.9 | — | — | — | — | — | — | — | — | — | — | — |
| Debt repaid | -1.1 | -0.5 | -0.4 | -1.3 | -0.6 | -1.0 | -1.1 | -1.1 | -1.2 | -2.1 | -1.6 | -2.0 |
| Effect of exchange rates | 5.8 | 0.7 | -1.3 | -0.1 | -1.7 | -1.3 | -0.5 | 0.4 | 0.5 | -0.3 | -0.1 | -0.3 |
| Net change in cash | 69.1 | -21.1 | 23.4 | -7.2 | -36.4 | 43.8 | -16.8 | -1.0 | -93.4 | 61.4 | -26.1 | -384 |
| Free cash flow | -34.1 | -82.9 | -49.1 | -65.5 | -113 | -43.7 | -76.0 | -69.8 | -126 | -122 | -129 | -99.1 |
| Levered free cash flow | -38.9 | -89.3 | 375 | -61.9 | 33.5 | 44.8 | -66.6 | -85.0 | -124 | -88.5 | -6.3 | -34.3 |
Financial statements of similar companies
Companies in the group: same industry, similar size
